Treatment of borderline personality disorder. Part I: pharmacotherapy Review article
Article Sidebar
Published:
Jun 30, 2013
Keywords:
borderline personality disorder, biological treatment
Main Article Content
Abstract
More and more patients are diagnosed as the borderline personality disorder (BPD). Usually, this group of people challenges seriously the whole staff, especially with no obvious standard of biological treatment. Olanzapine treatment is the only biological treatment that partially proved its effectiveness in randomized clinical trial. Some other drugs, both antipsychotics and antidepressants, may reduce the severity of symptoms of affective instability and impulsivity of BPD.
Article Details
Issue
Section
Articles
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright: © Medical Education sp. z o.o. License allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
1. Jakubik A. Mit osobowości pogranicznej. W: Studia z psychologii. Tom VII. Grochowska A, Jakubik A, Marcysiak IM, Siek S, Strzałecki A, Terelak J (red). Wydawnictwo ATK, Warszawa1996: 303-316.
2. DSM-V. DSM-5 Classification. Diagnostic and statistical manual of mental disorders. APA, Washington 2013.
3. ICD-10. Międzynarodowa Statystyczna Klasyfikacja Chorób i Problemów Zdrowotnych. Rewizja dziesiąta. Rozdział V: Zaburzenia psychiczne i zaburzenia zachowania (F00-F99). Wyd. Vesalius, Kraków 1994.
4. Mosiołek A, Grzesiewska J, Chilmończyk I, Łoza B. Osobowość pograniczna: stabilna czy niestabilna choroba psychiczna? Neuropsychiatria. Przegląd Kliniczny 2011; 3(1): 25-33.
5. Kernberg OF, Michels R. Borderline personality disorder. Am J Psychiatry 2009; 166 (5): 505-508.
6. Goldstain EG. Zaburzenia z pogranicza. GWP, Gdańsk 2003.
7. Akiskal HS, Chen SE, Davis GC, Puzantian VR, Kashgarian M, Bolinger JM. Borderline: an adjective in search of a noun. Journal Clinical of Psychiatry 1985; 46, 41-48.
8. Akiskal HS. Subaffective disorders: dysthymic, cyclothymic and bipolar disorders in the ‘borderline’ realm. Psychiat Clin N Amer 1981; 4: 25-46.
9. Soloff PH, Lis JA, Kelly T, Cornelius J, Ulrich R. Risk factors for suicidal behavior in borderline personality disorder. Am J Psychiatry 1994; 151 (9): 1316-1323.
10. Wöckel L, Goth K, Matic N, Zepf FD, Holtmann M, Poustka F. Psychopharmacotherapy in adolescents with borderline personality disorder in inpatient and outpatient psychiatric treatment. Kinder Jugendpsychiatr Psychother 2010; 38 (1): 37-49.
11. Stoffers J, Völlm BA, Rücker G, Timmer A, Huband N, Lieb K. Pharmacological interventions for borderline personality disorder. Cochrane Database Syst Rev 2010; 16 (6): CD005653.
12. Bellino S, Paradiso E, Bogetto F. Efficacy and tolerability of pharmacotherapies for borderline personality disorder. CNS Drugs 2008; 22(8): 671-692.
13. Rinne T, van den Brink W, Wouters L, van Dycka R. SSRI treatment of borderline personality disorder: a randomized, placebo- controlled clinical trial for female patients with borderline personality disorder. Am J Psychiatry 2002; 159(12): 2048-2054.
14. Markovitz P. Pharmacotherapy of impulsivity, aggression, and related disorders. W: Impulsivity and Aggression. John Wiley & Sons, New York 1995: 263-287.
15. Lieb K, Völlm B, Rücker G, Timmer A, Stoffers JM. Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials. Br J Psychiatry 2010; 196 (1): 4-12.
16. Hori A. Pharmacotherapy for personality disorders. Psychiatry Clin Neurosci 1998; 52(1): 13-19.
17. Mehlum L. Clinical challenges in the assessment and management of suicidal behaviour in patients with bordeline personality disorder. Epidemiol Psichiatr Soc 2009; 18(3): 184-190.
18. Shafti SS, Shahveisi B. Olanzapine versus haloperidol in the management of borderline personality disorder: a randomized double-blind trial. J Clin Psychopharmacol 2010; 30(1): 44-47.
19. Schulz SC, Zanarini MC, Bateman A, Bohus M, Detke HC, Trzaskoma Q, Tanaka Y, Lin D, Deberdt W, Corya S. Olanzapine for the treatment of borderline personality disorder: variable dose 12-week randomised double-blind placebo-controlled study. Br J Psychiatry 2008; 193(6): 485-492.
20. Linehan MM, McDavid JD, Brown MZ, Sayrs JH, Gallop RJ. Olanzapine plus dialectical behavior therapy for women with high irritability who meet criteria for borderline personality disorder: a double-blind, placebo-controlled pilot study. J Clin Psychiatry 2008; 69(6): 999-1005.
21. Grootens KP, Verkes RJ. Emerging evidence for the use of atypical antipsychotics in borderline personality disorder. Pharmacopsychiatry 2005; 38(1): 20-23.
21. Zanarini MC, Frankenburg FR, Parachini EA. A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine- fluoxetine combination in women with borderline personality disorder. J Clin Psychiatry 2004; 65(7): 903-907.
22. Hori A. Pharmacotherapy for personality disorders. Psychiatry Clin Neurosci 1998; 52(1): 13-19.
2. DSM-V. DSM-5 Classification. Diagnostic and statistical manual of mental disorders. APA, Washington 2013.
3. ICD-10. Międzynarodowa Statystyczna Klasyfikacja Chorób i Problemów Zdrowotnych. Rewizja dziesiąta. Rozdział V: Zaburzenia psychiczne i zaburzenia zachowania (F00-F99). Wyd. Vesalius, Kraków 1994.
4. Mosiołek A, Grzesiewska J, Chilmończyk I, Łoza B. Osobowość pograniczna: stabilna czy niestabilna choroba psychiczna? Neuropsychiatria. Przegląd Kliniczny 2011; 3(1): 25-33.
5. Kernberg OF, Michels R. Borderline personality disorder. Am J Psychiatry 2009; 166 (5): 505-508.
6. Goldstain EG. Zaburzenia z pogranicza. GWP, Gdańsk 2003.
7. Akiskal HS, Chen SE, Davis GC, Puzantian VR, Kashgarian M, Bolinger JM. Borderline: an adjective in search of a noun. Journal Clinical of Psychiatry 1985; 46, 41-48.
8. Akiskal HS. Subaffective disorders: dysthymic, cyclothymic and bipolar disorders in the ‘borderline’ realm. Psychiat Clin N Amer 1981; 4: 25-46.
9. Soloff PH, Lis JA, Kelly T, Cornelius J, Ulrich R. Risk factors for suicidal behavior in borderline personality disorder. Am J Psychiatry 1994; 151 (9): 1316-1323.
10. Wöckel L, Goth K, Matic N, Zepf FD, Holtmann M, Poustka F. Psychopharmacotherapy in adolescents with borderline personality disorder in inpatient and outpatient psychiatric treatment. Kinder Jugendpsychiatr Psychother 2010; 38 (1): 37-49.
11. Stoffers J, Völlm BA, Rücker G, Timmer A, Huband N, Lieb K. Pharmacological interventions for borderline personality disorder. Cochrane Database Syst Rev 2010; 16 (6): CD005653.
12. Bellino S, Paradiso E, Bogetto F. Efficacy and tolerability of pharmacotherapies for borderline personality disorder. CNS Drugs 2008; 22(8): 671-692.
13. Rinne T, van den Brink W, Wouters L, van Dycka R. SSRI treatment of borderline personality disorder: a randomized, placebo- controlled clinical trial for female patients with borderline personality disorder. Am J Psychiatry 2002; 159(12): 2048-2054.
14. Markovitz P. Pharmacotherapy of impulsivity, aggression, and related disorders. W: Impulsivity and Aggression. John Wiley & Sons, New York 1995: 263-287.
15. Lieb K, Völlm B, Rücker G, Timmer A, Stoffers JM. Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials. Br J Psychiatry 2010; 196 (1): 4-12.
16. Hori A. Pharmacotherapy for personality disorders. Psychiatry Clin Neurosci 1998; 52(1): 13-19.
17. Mehlum L. Clinical challenges in the assessment and management of suicidal behaviour in patients with bordeline personality disorder. Epidemiol Psichiatr Soc 2009; 18(3): 184-190.
18. Shafti SS, Shahveisi B. Olanzapine versus haloperidol in the management of borderline personality disorder: a randomized double-blind trial. J Clin Psychopharmacol 2010; 30(1): 44-47.
19. Schulz SC, Zanarini MC, Bateman A, Bohus M, Detke HC, Trzaskoma Q, Tanaka Y, Lin D, Deberdt W, Corya S. Olanzapine for the treatment of borderline personality disorder: variable dose 12-week randomised double-blind placebo-controlled study. Br J Psychiatry 2008; 193(6): 485-492.
20. Linehan MM, McDavid JD, Brown MZ, Sayrs JH, Gallop RJ. Olanzapine plus dialectical behavior therapy for women with high irritability who meet criteria for borderline personality disorder: a double-blind, placebo-controlled pilot study. J Clin Psychiatry 2008; 69(6): 999-1005.
21. Grootens KP, Verkes RJ. Emerging evidence for the use of atypical antipsychotics in borderline personality disorder. Pharmacopsychiatry 2005; 38(1): 20-23.
21. Zanarini MC, Frankenburg FR, Parachini EA. A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine- fluoxetine combination in women with borderline personality disorder. J Clin Psychiatry 2004; 65(7): 903-907.
22. Hori A. Pharmacotherapy for personality disorders. Psychiatry Clin Neurosci 1998; 52(1): 13-19.